The ABHD2 (α/β-hydrolase domain-containing protein 2) antibody is a key tool for studying the functional roles of ABHD2. a member of the serine hydrolase superfamily. ABHD2 is a transmembrane protein implicated in lipid metabolism, cell signaling, and reproductive biology. It gained prominence for its critical role in sperm activation, where it acts as a receptor for progesterone, triggering the release of endocannabinoids to induce the acrosome reaction necessary for fertilization (Miller et al., 2016). Beyond reproduction, ABHD2 is linked to cancer progression, inflammation, and lipid regulation, with studies suggesting its involvement in tumor cell migration, invasion, and metastasis through mechanisms like cytoskeletal remodeling.
ABHD2 antibodies, including monoclonal and polyclonal variants, are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect ABHD2 expression and localization in tissues or cultured cells. These antibodies help elucidate its interaction networks, post-translational modifications (e.g., phosphorylation), and tissue-specific expression patterns. Validated antibodies typically target conserved regions, such as the catalytic α/β-hydrolase domain, ensuring cross-reactivity in human, mouse, and rat models. Researchers rely on these antibodies to explore ABHD2’s pathophysiological roles, particularly in infertility, cancer, and metabolic disorders, making them essential for advancing therapeutic and diagnostic strategies.